An Australian healthcare giant that's trying to turn itself around after a torrid couple of years has accepted that its shareholders are frustrated.
The admission by chair Brian McNamee was made in CSL's annual report published on Thursday, just weeks after the blood plasma and vaccines supplier posted a shattering $3.7 billion annual loss.
